Published in Rev Urol on January 01, 2008
Status of radical prostatectomy in 2009: is there medical evidence to justify the robotic approach? Rev Urol (2009) 0.93
Counseling patients about sexual health when considering post-prostatectomy radiation treatment. Int J Impot Res (2009) 0.77
Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol (2008) 3.50
A brief male sexual function inventory for urology. Urology (1995) 2.80
Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke (2002) 2.24
Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol (2004) 2.15
Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care (2002) 1.88
Variation in continence and potency by definition. J Urol (2003) 1.75
Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol (2004) 1.62
Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol (2000) 1.40
Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol (2003) 1.31
The ability of axons to regenerate their growth cones depends on axonal type and age, and is regulated by calcium, cAMP and ERK. Eur J Neurosci (2005) 1.27
Signaling the pathway to regeneration. Neuron (2002) 1.21
PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol (1995) 1.09
Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology (2000) 1.07
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy. J Urol (2009) 1.07
Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. J Urol (2000) 1.01
Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res (1999) 1.00
Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol (1998) 1.00
Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J Clin Invest (1993) 0.96
Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. J Urol (2008) 0.96
Altered contractility of rabbit penile corpus cavernosum smooth muscle by hypoxia. J Urol (1996) 0.96
Differences in sexual function and quality of life after nerve sparing and nonnerve sparing radical retropubic prostatectomy. J Urol (2000) 0.95
Is sildenafil failure in men after radical retropubic prostatectomy (RRP) due to arterial disease? Penile duplex Doppler findings in 174 men after RRP. Int J Impot Res (2002) 0.89
Impotence. NIH Consens Statement (1993) 0.89
Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res (2005) 0.87
Fibrosis of corpus cavernosum in animals following cavernous nerve ablation. Asian J Androl (2004) 0.87
Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. Congest Heart Fail (2003) 0.87
Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells. J Steroid Biochem Mol Biol (2001) 0.85
Sildenafil citrate after radical retropubic prostatectomy. J Urol (1999) 0.84
Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP). Prostate Cancer Prostatic Dis (2004) 0.84
[Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy]. Hinyokika Kiyo (1993) 0.81
Penile oxygen saturation in the flaccid and erect penis in men with and without erectile dysfunction. J Androl (2006) 0.79
Treatment of obliterated membranous and bulbous urethras by direct vision internal urethrotomy. J Trauma (1987) 0.76
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA (2013) 3.40
Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol (2002) 2.96
Gleason 6 prostate cancer: serious malignancy or toothless lion? Oncology (Williston Park) (2014) 2.06
Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol (2005) 1.98
Posterior rhabdosphincter reconstruction during robotic assisted radical prostatectomy: results from a phase II randomized clinical trial. J Urol (2011) 1.84
Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology (2010) 1.78
An artificial somatic-autonomic reflex pathway procedure for bladder control in children with spina bifida. J Urol (2005) 1.78
hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther (2006) 1.69
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Ten-year outcomes of sexual function after radical prostatectomy: results of a prospective longitudinal study. Eur Urol (2013) 1.62
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest (2007) 1.59
Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol (2010) 1.58
Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy. Urology (2013) 1.56
Does a nerve-sparing technique or potency affect continence after open radical retropubic prostatectomy? BJU Int (2008) 1.53
The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms. J Urol (2007) 1.50
Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion. J Sex Med (2013) 1.47
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46
Proximal prostatic stem cells are programmed to regenerate a proximal-distal ductal axis. Stem Cells (2006) 1.43
Seminal vesicle abscess following prostate biopsy requiring transgluteal percutaneous drainage. Can J Urol (2013) 1.40
Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing post-prostatectomy hernia. BJU Int (2012) 1.39
Bladder neck contractures related to the use of Hem-o-lok clips in robot-assisted laparoscopic radical prostatectomy. Urology (2008) 1.37
Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol (2007) 1.36
Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol (2004) 1.27
Open Versus Laparoscopic Versus Robot-Assisted Laparoscopic Prostatectomy: The European and US Experience. Rev Urol (2010) 1.25
Influence of body weight and prostate volume on intraoperative, perioperative, and postoperative outcomes after radical retropubic prostatectomy. Urology (2003) 1.18
Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol (2007) 1.18
Vascular pseudoaneurysms in urology: clinical characteristics and management. J Endourol (2010) 1.14
Skin preparation for the prevention of surgical site infection: which agent is best? Rev Urol (2009) 1.14
Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med (2010) 1.13
Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res (2009) 1.13
Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol (2003) 1.12
Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. Rev Urol (2009) 1.12
Post-prostatectomy incontinence during sexual activity: a single center prevalence study. J Urol (2011) 1.09
The prostatic utricle is not a Müllerian duct remnant: immunohistochemical evidence for a distinct urogenital sinus origin. J Urol (2004) 1.08
Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol (2004) 1.08
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy. J Urol (2009) 1.07
Outcomes for men younger than 50 years undergoing radical prostatectomy. Urology (2005) 1.05
Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med (2004) 1.05
Removal of urinary catheter on postoperative day 3 or 4 after radical retropubic prostatectomy. Urology (2003) 1.02
Spontaneous renal artery dissection. Rev Urol (2007) 1.02
Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clin Trials (2009) 0.99
The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol (2005) 0.99
Plasmid-based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial. Isr Med Assoc J (2007) 0.97
Spontaneous retroperitoneal hemorrhage caused by segmental arterial mediolysis. Rev Urol (2006) 0.96
Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. Dev Biol (2011) 0.96
Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. J Urol (2008) 0.96
Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol (2011) 0.96
Patient centered outcomes in prostate cancer treatment: predictors of satisfaction up to 2 years after open radical retropubic prostatectomy. J Urol (2010) 0.96
Long-term continence outcomes in men undergoing radical prostatectomy for clinically localized prostate cancer. Eur Urol (2013) 0.95
Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int (2009) 0.95
Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med (2005) 0.95
Management of localized prostate cancer and an incidental ureteral duplication with upper pole ectopic ureter inserting into the prostatic urethra. Rev Urol (2008) 0.95
The New York University nerve sparing algorithm decreases the rate of positive surgical margins following radical retropubic prostatectomy. J Urol (2003) 0.94
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin Chem (2011) 0.94
PLP1 alternative splicing in differentiating oligodendrocytes: characterization of an exonic splicing enhancer. J Cell Biochem (2006) 0.92
Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep (2004) 0.92
Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. J Urol (2012) 0.91
Factors predisposing to the development of anastomotic strictures in a single-surgeon series of radical retropubic prostatectomies. BJU Int (2006) 0.91
Bmp7 functions via a polarity mechanism to promote cloacal septation. PLoS One (2012) 0.91
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol (2007) 0.91
Managing and preventing acute urinary retention. Rev Urol (2005) 0.90
Testosterone in prostate cancer: the Bethesda consensus. BJU Int (2011) 0.90
LEF1 identifies androgen-independent epithelium in the developing prostate. Mol Endocrinol (2011) 0.88
Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology (2008) 0.88
Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol (2005) 0.88
Open versus laparoscopic radical prostatectomy. Rev Urol (2005) 0.87
Gene polymorphisms and prostate cancer: the evidence. BJU Int (2009) 0.86
Evaluating men with benign prostatic hyperplasia. Rev Urol (2004) 0.85
Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol (2008) 0.85
Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? Urology (2009) 0.85
Long-term satisfaction and predictors of use of intracorporeal injections for post-prostatectomy erectile dysfunction. J Urol (2012) 0.84
Durability and retreatment rates of minimal invasive treatments of benign prostatic hyperplasia: a cross-analysis of the literature. Can J Urol (2010) 0.84
Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. Oncotarget (2014) 0.84
The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev Urol (2006) 0.84
Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence. Eur Urol (2011) 0.84
Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. Carcinogenesis (2012) 0.84
Time to return to work and physical activity following open radical retropubic prostatectomy. J Urol (2006) 0.83
Pharmacotherapy for erectile dysfunction. J Sex Med (2004) 0.83
Intraoperative frozen section analysis of urethral margin biopsies during radical prostatectomy. Urology (2011) 0.83
Rectal injury during robot-assisted radical prostatectomy: incidence and management. J Urol (2011) 0.83
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology (2002) 0.83
Tamsulosin reduces the incidence of acute urinary retention following early removal of the urinary catheter after radical retropubic prostatectomy. Urology (2003) 0.83
Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol (2005) 0.83
Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys (2010) 0.82
Comparison of health-related quality-of-life outcomes for African-American and Caucasian-American men after radical prostatectomy. BJU Int (2012) 0.82
A review of surgical techniques for radical prostatectomy. Rev Urol (2005) 0.82
Reoperation versus observation in men with major bleeding after radical retropubic prostatectomy. Urology (2005) 0.82
Benign prostatic hyperplasia: current clinical practice. Prim Care (2010) 0.82
Blood loss during radical prostatectomy: impact on clinical, oncological and functional outcomes and complication rates. BJU Int (2011) 0.82
Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol (2005) 0.81
"Learning curve" may not be enough: assessing the oncological experience curve for robotic radical prostatectomy. J Endourol (2010) 0.81
The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia. Rev Urol (2008) 0.81
Postoperative blood loss predicts the development of urinary extravasation on cystogram following radical retropubic prostatectomy. J Urol (2006) 0.81
Isolation of mouse THP gene promoter and demonstration of its kidney-specific activity in transgenic mice. Am J Physiol Renal Physiol (2002) 0.80
Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. Urology (2005) 0.79